Development and 10-year history of a biosimilar: the example of Binocrit
Patent expirations for several biological products have prompted the development of alternative versions, termed ‘biosimilars’, which have comparable quality, safety and efficacy to a licensed biological medicine (also referred to as the ‘reference’ medicine). The first biosimilars developed in onco...
Main Authors: | Matti Aapro, Andriy Krendyukov, Nadja Höbel, Andreas Seidl, Pere Gascón |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-04-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835918768419 |
Similar Items
-
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
by: Dellanna F, et al.
Published: (2017-12-01) -
Innovative oncology products: time to revisit the strategy development?
by: Andriy Krendyukov
Published: (2019-09-01) -
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
by: Borrás Pérez MV, et al.
Published: (2017-05-01) -
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
by: Matti Aapro, et al.
Published: (2012-05-01) -
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
by: López-Siguero JP, et al.
Published: (2017-05-01)